As part of a $500 million agreement with the FDA over manufacturing problems, Schering-Plough has dropped 72 drugs. The drug company had not been marketing the mostly older products, which were available only through its Kenilworth Pharmaceuticals division, said a Schering spokesman. Discontinued ...